UBS Group’s Globus Medical GMED Stock Holding History

UBS Group’s Portfolio GMED Stock Details GMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-213,100	Closed	-$18.6M	–	10754
2025 Q4	$18.6M	Buy	+213,100	New	+$16.2M	﹤0.01%	2649

Other funds holding GMED

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sculptor Capital New York $12.3B AUM 40.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

UBS Group's GMED Position: Q2 2026 in Review

UBS Group increased its Globus Medical (GMED) stake by 54% in Q2 2026, buying an estimated $24.7M and bringing the position to 834,191 shares worth $65.9M. The position accounts for 0.01% of the portfolio, ranked #1482.

UBS Group first reported a position in GMED in Q4 2014 and has held it in 47 quarters since. The position peaked at $73.8M in Q1 2025. 601 funds tracked by Wall St. Rank hold GMED as of Q2 2026.

UBS Group held 834,191 shares of Globus Medical worth $65.9M as of Q2 2026.
UBS Group bought 291,079 Globus Medical shares in Q2 2026, an estimated $24.7M.
Globus Medical made up 0.01% of UBS Group's portfolio in Q2 2026, its #1482 holding.
UBS Group first reported a position in Globus Medical in Q4 2014 and has held it in 47 quarters since.
UBS Group's Globus Medical position peaked at $73.8M in Q1 2025.
601 funds tracked by Wall St. Rank held Globus Medical as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.